A nurse is teaching a client who has osteoarthritis and is prescribed celecoxib (Celebrex), a selective COX-2 inhibitor. What should the nurse include in the teaching?
A.
The drug has less gastrointestinal toxicity than nonselective COX inhibitors because it does not interfere with gastric mucosal protection by prostaglandins.
B.
The drug has more anti-inflammatory and analgesic effects than nonselective COX inhibitors because it blocks both COX-1 and COX-2 enzymes.
C.
The drug has less cardiovascular risk than nonselective COX inhibitors because it inhibits vasodilatory and antiplatelet prostaglandins produced by COX-2 in the endothelium.
D.
The drug has more antipyretic and antiplatelet effects than nonselective COX inhibitors because it blocks the production of prostaglandins involved in fever and platelet aggregation.
The Correct Answer and Explanation is:
The correct answer is A: The drug has less gastrointestinal toxicity than nonselective COX inhibitors because it does not interfere with gastric mucosal protection by prostaglandins.
Explanation:
Celecoxib (Celebrex) is a selective COX-2 inhibitor used to manage symptoms of osteoarthritis and other conditions characterized by pain and inflammation. To understand why option A is correct, it’s important to delve into the role of COX enzymes and the implications of their inhibition.
COX Enzymes:
- COX-1 (Cyclooxygenase-1) is an enzyme that helps produce prostaglandins involved in maintaining gastric mucosal integrity, protecting the stomach lining from acid damage, and supporting platelet function.
- COX-2 (Cyclooxygenase-2) is an enzyme primarily involved in the production of prostaglandins that mediate inflammation, pain, and fever. COX-2 expression is typically induced at sites of inflammation.
Nonselective COX Inhibitors:
- Traditional nonselective COX inhibitors, such as ibuprofen and naproxen, inhibit both COX-1 and COX-2. While they are effective in reducing inflammation and pain, their inhibition of COX-1 can disrupt the protective prostaglandins in the stomach, leading to increased risk of gastrointestinal (GI) issues such as ulcers and bleeding.
Celecoxib (Celebrex) as a Selective COX-2 Inhibitor:
- Celecoxib selectively inhibits COX-2 while sparing COX-1. By targeting COX-2, it reduces inflammation and pain without significantly affecting COX-1. This selectivity is associated with a lower incidence of gastrointestinal toxicity because it does not interfere with the protective prostaglandins produced by COX-1 in the gastric mucosa.
Why Other Options are Incorrect:
- B: Celecoxib does not have more anti-inflammatory and analgesic effects than nonselective COX inhibitors. It specifically targets COX-2, which primarily impacts inflammation and pain, but does not block COX-1, which is important for other functions.
- C: Celecoxib does not inherently have less cardiovascular risk. In fact, selective COX-2 inhibitors have been associated with an increased risk of cardiovascular events because they can affect vascular prostaglandins that promote vasodilation and inhibit platelet aggregation.
- D: Celecoxib is not particularly known for its antipyretic (fever-reducing) and antiplatelet effects compared to nonselective COX inhibitors. It primarily targets inflammation and pain and has minimal impact on platelet function and fever.
In summary, Celecoxib is favored for its reduced gastrointestinal toxicity compared to nonselective COX inhibitors, thanks to its selective inhibition of COX-2 and sparing of COX-1, which maintains gastric mucosal protection.